A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases. Our mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, we are overcoming complex drug development challenges to make new therapies available to the rare disease community. We have a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Our team has specialized expertise and a track record of success in advancing promising therapies that face complex clinical, regulatory, and commercial challenges with an approach that balances science with patient need. Following the U.S.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 84M | - | 27M | - | - | 13M |
| Net Income | 35M | -106M | -46M | -27M | -63M | -13M |
| EPS | $0.44 | $-1.95 | $-0.85 | $-0.62 | $-1.82 | $-3.21 |
| Free Cash Flow | 0 | -70M | -34M | -19M | 10M | -2.0M |
| ROIC | -41.2% | -105.1% | -68.8% | -30.5% | - | -39.5% |
| Gross Margin | - | - | 97.2% | - | - | - |
| Debt/Equity | 0.46 | 1.50 | 0.08 | 0.17 | - | -1.02 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -88M | -87M | -50M | -43M | 7.7M | -5.6M |
| Operating Margin | -103.9% | - | -180.6% | - | - | -42.2% |
| ROE | 26.5% | -207.8% | -74.4% | -30.3% | - | - |
| Shares Outstanding | 56M | 54M | 54M | 43M | 35M | 34M |
| Metric | 2014 | 2015 | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0 | 0 | 13M | 13M | N/A | N/A | 27M | N/A | 84M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | 97.2% | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -16M | -23M | -20M | -5.6M | 7.7M | -43M | -50M | -87M | -88M |
| Op. Margin | N/A | N/A | -158.4% | -42.2% | N/A | N/A | -180.6% | N/A | -103.9% |
| Net Income | -24M | -55M | -25M | -13M | -63M | -27M | -46M | -106M | 35M |
| Net Margin | N/A | N/A | -191.0% | -96.0% | N/A | N/A | -167.7% | N/A | 41.9% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||
| ROIC | -94.7% | -32.3% | -152.9% | -39.5% | N/A | -30.5% | -68.8% | -105.1% | -41.2% |
| ROE | N/A | N/A | N/A | N/A | N/A | -30.3% | -74.4% | -207.8% | 26.5% |
| ROA | -178.3% | -157.4% | -233.4% | -113.8% | -47.3% | -23.2% | -26.7% | -60.2% | 13.1% |
| Cash Flow | |||||||||
| Op. Cash Flow | -15M | -20M | -24M | -1.9M | 10M | -19M | -34M | -70M | -23M |
| Free Cash Flow | -15M | -20M | -24M | -2.0M | 10M | -19M | -34M | -70M | 0 |
| Owner Earnings | -15M | -23M | -28M | -4.7M | 7.7M | -24M | -40M | -91M | -45M |
| CapEx | 49K | 135K | 26K | 33K | 102K | 93K | 296K | 0 | 0 |
| Maint. CapEx | 75K | 84K | 304K | 273K | 257K | 944K | 1.0M | 6.4M | 6.4M |
| Growth CapEx | 0 | 51K | 0 | 0 | 0 | 0 | 0 | N/A | 0 |
| D&A | 75K | 84K | 304K | 273K | 257K | 944K | 1.0M | 6.4M | 6.4M |
| CapEx/OCF | N/A | N/A | N/A | N/A | 1.0% | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 4.7M | 3.4M | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 2.6% | 1.1% | N/A | 0.0% |
| Stock-Based Comp | 214K | 2.4M | 4.4M | 2.5M | 2.4M | 4.3M | 6.0M | 15M | 15M |
| Debt Repayment | 0 | 0 | 300K | 34K | 2.9M | 0 | 18M | 43M | 43M |
| Balance Sheet | |||||||||
| Net Debt | -8.8M | -50M | 74M | 63M | -112M | -53M | -38M | 26M | 6.9M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 54M |
| Long-Term Debt | 1.5M | 1.1M | 77M | 68M | 0 | 13M | 5.1M | 60M | 60M |
| Debt/Equity | -0.03 | -0.11 | -1.04 | -1.02 | N/A | 0.17 | 0.08 | 1.50 | 0.46 |
| Interest Coverage | -10.2 | -8.5 | -4.2 | -1.2 | 34.2 | -127.1 | -33.0 | -11.8 | -11.8 |
| Equity | -49M | -10M | -74M | -66M | N/A | 75M | 62M | 40M | 133M |
| Total Assets | 14M | 56M | 11M | 11M | 133M | 115M | 172M | 178M | 270M |
| Total Liabilities | 62M | 66M | 85M | 78M | N/A | 40M | 110M | 138M | 137M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | 0 | 74M | 74M | 74M |
| Retained Earnings | -50M | -105M | -246M | -258M | -267M | -354M | -400M | -505M | -505M |
| Working Capital | 6.3M | 46M | 1.5M | 846K | 111M | 81M | 13M | 52M | 52M |
| Current Assets | 10M | 54M | 7.0M | 8.4M | 115M | 93M | 87M | 86M | 86M |
| Current Liabilities | 3.9M | 8.3M | 5.4M | 7.5M | 4.2M | 12M | 74M | 34M | 34M |
| Per Share Data | |||||||||
| EPS | -164.32 | -118.72 | -13.23 | -3.21 | -1.82 | -0.62 | -0.85 | -1.95 | 0.44 |
| Owner EPS | -16.51 | -49.35 | -1.00 | -0.14 | 0.22 | -0.55 | -0.75 | -1.68 | -0.79 |
| Book Value | -53.53 | -21.98 | -2.62 | -1.93 | N/A | 1.73 | 1.14 | 0.73 | 2.37 |
| Cash Flow/Share | -16.19 | -44.02 | -0.84 | -0.06 | 0.30 | -0.43 | -0.62 | -1.29 | 0.74 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.9M | 0.5M | 28.4M | 34.4M | 34.5M | 43.4M | 54.1M | 54.1M | 56.3M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 21.9 |
| P/FCF | N/A | N/A | N/A | N/A | 28.7 | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | 23.8 | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | 2.4 | 5.0 | 11.4 | 4.1 |
| Price/Sales | N/A | N/A | 48.6 | 19.4 | N/A | N/A | 10.0 | N/A | 6.5 |
| FCF Yield | N/A | -14.5% | -12.5% | -0.4% | 3.5% | -10.2% | -11.0% | -15.3% | N/A |
| Market Cap | N/A | 140M | 190M | 498M | 296M | 184M | 308M | 454M | 547M |
| Avg. Price | N/A | 267.44 | 21.97 | 7.48 | 9.70 | 5.48 | 5.07 | 6.55 | 9.72 |
| Year-End Price | N/A | 304.64 | 6.69 | 14.47 | 8.58 | 4.23 | 5.70 | 8.39 | 9.72 |
ZEVRA THERAPEUTICS, INC. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 97.2%. At current prices, the estimated annualized return to fair value is +27.4%.
ZEVRA THERAPEUTICS, INC. (ZVRA) has a 5-year average return on invested capital (ROIC) of -61.0%. This is below average and may indicate limited pricing power.
ZEVRA THERAPEUTICS, INC. (ZVRA) has a market capitalization of $547M. It is classified as a small-cap stock.
ZEVRA THERAPEUTICS, INC. (ZVRA) does not currently pay a regular dividend.
ZEVRA THERAPEUTICS, INC. (ZVRA) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ZEVRA THERAPEUTICS, INC. (ZVRA) generated $-70 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ZEVRA THERAPEUTICS, INC. (ZVRA) has a debt-to-equity ratio of 1.50. This indicates higher leverage, which may increase financial risk.
ZEVRA THERAPEUTICS, INC. (ZVRA) reported earnings per share (EPS) of $-1.95 in its most recent fiscal year.
ZEVRA THERAPEUTICS, INC. (ZVRA) has a return on equity (ROE) of -207.8%. A negative ROE may indicate losses or negative equity.
ZEVRA THERAPEUTICS, INC. (ZVRA) has a 5-year average gross margin of 97.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 8 years of financial data for ZEVRA THERAPEUTICS, INC. (ZVRA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ZEVRA THERAPEUTICS, INC. (ZVRA) has a book value per share of $0.73, based on its most recent annual SEC filing.